SKIN CELLS CAN BE ENGINEERED IN TO PULMONARY VALVES FOR PEDIATRIC PATIENTS
Researchers have found
a way to take a pediatric patient's skin cells, reprogram the skin cells to
function as heart valvular cells, and then use the cells as part of a
tissue-engineered pulmonary valve. A proof of concept study published in the
September 2014 issue of The Annals of Thoracic Surgery provides more detail on
this scientific development
"Current valve
replacements cannot grow with patients as they age, but the use of a
patient-specific pulmonary valve would introduce a 'living' valvular construct
that should grow with the patient. Our study is particularly important for
pediatric patients who often require repeated operations for pulmonary valve
replacements," said lead author David L. Simpson, PhD, from the University
of Maryland School of Medicine in Baltimore.
Dr. Simpson, senior
co-author Sunjay Kaushal, MD, PhD, and colleagues designed a process to
transform skin cells from a simple biopsy into cells that become an important
ingredient in a tissue-engineered pulmonary valve.
The pulmonary valve
is a crescent-shaped valve that lies between the heart's right ventricle and
pulmonary artery. It is responsible for moving blood from the heart into the
lungs.
While the study was
conducted in vitro (outside of the body), the next step will be implanting the
new valves into patients to test their durability and longevity.
"We created a
pulmonary valve that is unique to the individual patient and contains living
cells from that patient. That valve is less likely to be destroyed by the
patient's immune system, thus improving the outcome and hopefully increasing
the quality of life for our patient," said Dr. Kaushal. "In the
future, it may be possible to generate this pulmonary valve by using a blood
sample instead of a skin biopsy."
Dr. Simpson added
that he hopes the study will encourage additional research in tissue
engineering and entice more people to enter the field, "Hopefully, growing
interest and research in this field will translate more quickly into clinical
application."
It is estimated that
nearly 800 patients per year could potentially benefit from bioengineered
patient-specific pulmonary valves, according to data from the STS Congenital
Heart Surgery Database. The Database, which collects information from more than
95% of hospitals in the US and Canada that perform pediatric and congenital
heart surgery, shows that approximately 3,200 patients underwent pulmonary
valve replacement during a 4-year period from January 2010 to December 2013.
Comments
Post a Comment